CONSORT recommendations for reporting harms in clinical trials

By  

Reactions Weekly, Vol. 1, Iss. 1031, 2004-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

CONSORT recommendations for reporting harms in clinical trials

By  

Inpharma, Vol. 1, Iss. 1467, 2004-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Myelotoxicity and Dose Intensity of Chemotherapy: Reporting Practices From Randomized Clinical Trials

By Dale David C.   McCarter Gordon C.   Crawford Jeffrey   Lyman Gary H.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 1, Iss. 3, 2003-07 ,pp. : 440-454

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

A Review of: “Interpreting and Reporting Clinical Trials: A Guide to the CONSORT Statement and the Principles of Randomised Controlled Trials, by A. Keech, V. Gebski, and R. Pike (eds.)”

By Simon Steve  

Journal of Biopharmaceutical Statistics, Vol. 18, Iss. 4, 2008-07 ,pp. : 802-804

Taylor & Francis Ltd

Access to resources Recommend Favorite

A Review of: “Randomized Clinical Trials: Design, Practice and Reporting, by D. Machin and P. M. Fayers”

By Assaid Christopher  

Journal of Biopharmaceutical Statistics, Vol. 21, Iss. 2, 2011-03 ,pp. : 367-370

Taylor & Francis Ltd

Access to resources Recommend Favorite